ABT vs AMPH: fair value comparison
Abbott Laboratories and Amphastar Pharmaceuticals, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ABT currently sits closer to the top of our ranking by discount to fair value.
| ABT | AMPH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $99.60 | $25.87 |
| 12-month range | $82.56–$130.59 | $16.87–$29.40 |
| Rank by discount to fair value | #26 of 108 Healthcare | #27 of 108 Healthcare |
| Quality grade | B | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ABT fair value analysis · AMPH fair value analysis